97175 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
EPHA3 DIRECTED CAR-T CELLS FOR TREATMENT OF TUMORS
#302ANTI-PROGRAMMED DEATH-LIGAND 1 (PD-L1) ANTIBODIES
#303CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPY
#304COMBINATIONS OF STAT-INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT AND/OR MANAGEMENT OF CANCER
#305BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#306"TWO-IN-ONE"-ANTIBODIES BINDING TO EGFR/PD-L1-DOUBLE POSITIVE CELLS
#307BISPECIFIC ANTIBODIES AGAINST CD277 AND A TUMOR-ANTIGEN
#308COMPOSITIONS AND METHODS FOR T CELL DELIVERY OF THERAPEUTIC MOLECULES
#309METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#310PD-L1 and OX40 Binding Proteins for Cancer Regulation
#311NOVEL METHODS OF THERAPY
#312HUMAN ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF
#313COMPOSITIONS COMPRISING AN ANTI-LAG-3 ANTIBODY OR AN ANTI-LAG-3 ANTIBODY AND AN ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY
#314COMPOSITIONS AND METHODS OF TREATMENT FOR CANCERS
#315USE OF TUMOR MUTATIONAL BURDEN AS A PREDICTIVE BIOMARKER FOR IMMUNE CHECKPOINT INHIBITOR VERSUS CHEMOTHERAPY EFFECTIVENESS IN CANCER TREATMENT
#316IMMUNOSUPPRESIVE AGENT
#317ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF
#318ANTI-PDL1 ANTIBODY FORMULATIONS
#319ANTI- PROGRAMMED DEATH-LIGAND 1 (PD-L1) ANTIBODY MOLECULES, ENCODING POLYNUCLEOTIDES, AND METHODS OF USE
#320B7-H3 TARGETING FUSION PROTEINS AND METHODS OF USE THEREOF
#321METHODS FOR MODULATING AN IMMUNE RESPONSE
#322NOVEL INTERFERON VARIANTS AND BIFUNCTIONAL FUSION MOLECULES THEREOF
#323METHODS AND COMPOSITIONS RELATED TO NK CELL AND ANTI-PDL1 CANCER THERAPIES
#324METHODS AND COMPOSITIONS COMPRISING B7H3 CHIMERIC ANTIGEN RECEPTORS
#325ANTI-B7-H7 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF
#326DEVELOPMENT OF NOVEL PDL1 SINGLE-DOMAIN ANTIBODY
#327ANTI-B7-H4 ANTIBODY, AND PREPARATION METHOD THEREFOR AND USE THEREOF
#328OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF
#329METHODS FOR MODULATING AN IMMUNE RESPONSE
#330COMBINATION THERAPIES FOR TREATING CANCERS
#331SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
#332BISPECIFIC RECOMBINANT PROTEIN AND USE THEREOF
#333Combination Therapy Involving Anti-CD39 Antibodies and Anti-PD-1 or Anti-PD-L1 Antibodies
#334DUAL SPECIFICITY ANTIBODIES TO PD-L1 AND PD-L2 AND METHODS OF USE THEREFOR
#335Antibodies Binding to Vista at Acidic pH
#336BUTYROPHILIN (BTN) 3A ACTIVATING ANTIBODIES FOR USE IN METHODS FOR TREATING INFECTIOUS DISORDERS
#337T CELL ENGAGER MOLECULES AND USES THEREOF
#338METHODS OF TREATING CANCER USING ANTIBODIES AND MOLECULES THAT IMMUNOSPECIFICALLY BIND TO BTN1A1
#339ANTIBODY-CONJUGATED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES
#340Engineered Probiotics for Colorectal Cancer Screening, Prevention, and Treatment
#341INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1), COMBINATIONS AND USES THEREOF
#342CD3-Binding Molecules Capable of Binding to Human and Non-Human CD3
#343ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES
#344MODULATION OF SUV39H1 EXPRESSION BY RNAS
#345METHODS OF TREATING CANCER WITH A COMBINATION OF A PD1 INHIBITOR AND A TARGETED IMMUNOCYTOKINE
#346VISTA ANTAGONIST AND METHODS OF USE
#347BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICRENVIRONMENT
#348BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT
#349ACTIVATABLE BISPECIFIC ANTI-CD3 AND ANTI-PD-L1 PROTEINS AND USES THEREOF
#350ANTAGONISTIC PD-1, PD-L1 AND LAG-3 BINDING PROTEINS
#351NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF
#352KIR3DL3 AS AN HHLA2 RECEPTOR, ANTI-HHLA2 ANTIBODIES, AND USES THEREOF
#353HIV VACCINES AND METHODS OF USING
#354ANTIBODY INDUCING IMMUNE TOLERANCE, INDUCED LYMPHOCYTE, AND CELL THERAPY AGENT THERAPEUTIC METHOD USING INDUCED LYMPHOCYTE
#355ANTI-B7-H3 COMPOUNDS AND METHODS OF USE
#356METHODS TO ENHANCE THERAPEUTIC EFFICACY IN MELANOMA VIA MODULATION OF CELL SURFACE PD-L1/L2
#357BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#358BISPECIFIC ANTIBODY BINDING TO B7H3 AND NKP30, AND APPLICATION THEREOF
#359HUMAN ANTIBODIES TO PD-L1
#360MULTISPECIFIC POLYPEPTIDE CONSTRUCTS CONTAINING A CONSTRAINED CD3 BINDING DOMAIN AND A RECEPTOR BINDING REGION AND METHODS OF USING THE SAME
#361ANTI-ILT3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#362COMPOSITION AND METHOD OF USE RECOMBINANT FUSION PROTEIN TO GENERATE CAR-IMMUNE CELLS
#363GENETICALLY MODIFIED MICE FOR PREPARING ANTIBODIES AND PREPARATION METHOD THEREFOR
#364CHIMERIC POXVIRUS COMPOSITIONS AND USES THEREOF
#365METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#366GENERATION OF CHIMERIC ANTIGEN RECEPTOR mRNA MOLECULES FOR EXPRESSION IN PRIMARY NK CELLS
#367BISPECIFIC HUMANIZED SINGLE DOMAIN ANTIBODY TO PD-L1 AND CD47, AND USE THEREOF
#368NK/MONOCYTE ENGAGERS
#369COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER CHARACTERIZED WITH PCSK9 EXPRESSION
#370COMBINATION THERAPY USING EXOSOME SECRETION INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR
#371COMBINED USE OF MULTIKINASE INHIBITOR
#372PRODUCTION METHOD FOR BISPECIFIC ANTIBODY
#373PD-L1 ANTIGEN BINDING PROTEIN AND USE THEREOF
#374BISPECIFIC BINDING PROTEINS AND USES THEREOF
#375METHODS AND COMPOSITIONS FOR DELIVERY OF IMMUNOTHERAPY AGENTS ACROSS THE BLOOD-BRAIN BARRIER TO TREAT BRAIN CANCER
#376Anti-B7-H4 Chimeric Antigen Receptor-Modified NK-92 Cells
#377ANTI-PD-L1 ANTIBODY, ANTI-PD-1 ANTIBODY, AND THE USE OF INHIBITOR TARGETING PD-1/PD-L1 AND COX-2 INHIBITOR
#378ANTIBODIES TARGETING PDL1 AND METHODS OF USE THEREOF
#379FC VARIANT COMPOSITIONS AND METHODS OF USE THEREOF
#380METHODS TO ENHANCE EFFICACY OF COMBINED TARGETING OF IMMUNE CHECKPOINT AND MAPK PATHWAYS
#381TREATMENT OF CANCER WITH COMBINATIONS OF IMMUNOREGULATORY AGENTS
#382AGONISTIC CD28 ANTIGEN BINDING MOLECULES TARGETING HER2
#383METHODS AND COMPOSITIONS FOR PROMOTING AND POTENTIATING T-CELL MEDIATED IMMUNE RESPONSES THROUGH ADCC TARGETING OF CD39 EXPRESSING CELLS
#384CD27 AGONISTS
#385DUAL SPECIFICITY ANTIBODIES TO HUMAN PD-L1 AND PD-L2 AND METHODS OF USE THEREFOR
#386HIGH AFFINITY B7-H6 ANTIBODIES AND ANTIBODY FRAGMENTS
#387COMPOSITIONS AND METHODS OF TREATING MELANOMA
#388PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER OR INFLAMMATORY DISEASE
#389BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#390RECEPTOR FOR VISTA
#391Use of PD-L1 Low Expression Status to Select Subjects for Cancer Immunotherapy
#392ANTI-B7-H3 MONOCLONAL ANTIBODY AND USE THEREOF IN CELL THERAPY
#393USE OF ANTI-PD-L1/CD47 BISPECIFIC ANTIBODY IN TREATMENT OF DISEASES
#394Anti-CD112R Compositions and Methods
#395HIV VACCINES AND METHODS OF USING
#396ANTIBODY-DRUG CONJUGATE
#397BIOMARKERS FOR PREDICTING ELIGIBILITY FOR AN ANTI-ILT4 AND ANTI-PD-1 COMBINATION THERAPY
#398BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOF
#399GUIDED COMBINATIONAL THERAPEUTIC ANTIBODY
#400FUSION PROTEIN OF INTERFERON (IFN) AND ANTI-PD-L1 ANTIBODY AND USE THEREOF
#401ANTI-B7H6 SCFV ANTIBODY, ITS CODING GENES AND THE APPLICATION THEREOF
#402TREATMENT OF LAG-3 POSITIVE TUMORS
#403ANTIBODY-CYTOKINE FUSION PROTEINS AND APPLICATIONS THEREOF
#404MUTANT ANTI-CTLA-4 ANTIBODIES WITH IMPROVED IMMUNOTHERAPEUTIC EFFECT BUT ATTENUATED ADVERSE EFFECTS
#405BISPECIFIC PD-L1xCD28 ANTIBODIES AND METHODS OF USE THEREOF
#406LAIR-2 Compositions and Methods
#407METHODS AND MATERIALS FOR TREATING CANCER
#408Formulations Comprising a SADA Complex
#409Pharmaceutical Composition Comprising Salmonella Strain and Immune Checkpoint Inhibitor as Active Ingredient for Prevention or Treatment of Cancer
#410GENE EDITING METHODS FOR MODULATING EXPRESSION OF ID-3, AN INHIBITOR OF DNA-BINDING TRANSCRIPTION FACTORS, THEREBY AFFECTING T-CELL FUNCTION
#411Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
#412BLOCKING AND NON-BLOCKING SINGLE DOMAIN ANTIBODIES AND USES THEREOF
#413NUCLEIC ACID CONSTRUCTS FOR CO-EXPRESSION OF CHIMERIC ANTIGEN RECEPTOR AND TRANSCRIPTION FACTOR, CELLS CONTAINING AND THERAPEUTIC USE THEREOF
#414B7H4 ANTIBODY-DRUG CONJUGATE AND USE THEREOF
#415ANTI-CD276 AND ANTI-CD99 LOGIC GATED CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER
#416GLUCOCORTICOID RECEPTOR BLOCKADE WITH MIFEPRISTONE TO SENSITIZE PANCREATIC CANCER TO IMMUNOTHERAPY
#417ANTI-BCMA NANOBODY AND USE THEREOF
#418A BISPECIFIC ANTI-PD-L1/VEGF ANTIBODY AND USES THEREOF
#419METHODS OF TREATING COLORECTAL CANCER
#420METHOD FOR THE REVIVAL OF MICROGLIA AND ASTROCYTES AND APPLICATIONS THEREOF
#421IRF-4 ENGINEERED T CELLS AND USES THEREOF IN TREATING CANCER
#422SINGLE DOMAIN ANTIBODY LIBRARIES WITH MAXIMIZED ANTIBODY DEVELOPABILITY CHARACTERISTICS
#423IMMUNOMODULATORY TRISPECIFIC T CELL ENGAGER FUSION PROTEINS
#424Bispecific Antibody against TIGIT and PD-L1, and Pharmaceutical Composition Thereof and Use Thereof
#425ANTI-CANINE PD-L1 ANTIBODIES
#426ANTI-B7H3 ANTIBODY AND USE THEREOF
#427Use of a Checkpoint Inhibitor in Combination with Ultralow Dose Whole Body Irradiation
#428NATURAL KILLER CELL-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF
#429BETA-GLUCAN IMMUNOTHERAPIES AFFECTING THE IMMUNE MICROENVIRONMENT
#430Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#431MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION THERAPY
#432BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGF-BETA AND USES THEREOF
#433ACTIVATABLE BISPECIFIC ANTI-CD47 AND ANTI-PD-L1 PROTEINS AND USES THEREOF
#434ANTI-B7-H6 ANTIBODY, FUSION PROTEINS, AND METHODS OF USING THE SAME
#435HUMAN CD276-TARGETING MONOCLONAL ANTIBODY AND APPLICATION THEREOF
#436METHOD FOR INHIBITING CARDIAC FIBROBLAST TRANSDIFFERENTIATION
#437NEOADJUVANT USAGE OF PLANT VIRUS OR VIRUS-LIKE PARTICLES FOR CANCER TREATMENT
#438COMBINATION OF A PD-1 ANTAGONIST AND A VEGF-R/FGFR/RET TYROSINE KINASE INHIBITOR FOR TREATING CANCER
#439PD-L1 TARGETING FUSION PROTEINS AND METHODS OF USE THEREOF
#440PILRA ANTIBODIES AND METHODS OF USE THEREOF
#441METHODS FOR TREATMENT OF CANCER WITH AN ANTI-TIGIT ANTAGONIST ANTIBODY
#442SEQUENTIAL TREATMENT OF CANCERS USING 6-THIO-dG, CHECKPOINT INHIBITORS AND RADIATION THERAPY
#443CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
#444ANTIBODIES AGAINST ILT4, BISPECIFIC ANTI-ILT4/PD-L1 ANTIBODY AND USES THEREOF
#445Linker Polypeptides
#446USE OF ANTI-B7H3 ANTIBODIES FOR TREATING CANCER IN THE CENTRAL NERVOUS SYSTEM
#447T CELL RECEPTOR RECOGNIZING R175H MUTATION IN P53 AND ITS APPLICATION
#448MOLECULES THAT BIND TO CD276 POLYPEPTIDES
#449TLR7 AGONIST AND COMBINATIONS FOR CANCER TREATMENT
#450Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof
#451MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION WITH ANTI PD-1 ANTIBODIES FOR TREATING CANCERS
#452ASSOCIATION OF A FAECALIBACTERIUM PRAUSNITZII STRAIN AND ANTI-PD-1, ANTI-PD-L1 OR ANTI-CTLA-4 ANTIBODIES FOR THE TREATMENT OF CANCER
#453NOVEL COMBINATION OF SEROTONIN RECEPTOR (5-HTR2B) ANTAGONIST AND AN IMMUNOMODULATOR AND CHEMOTHERAPEUTIC DRUGS FOR INHIBITION OF CANCER
#454CLINICAL FORMULATIONS OF ANTI-TIGIT ANTIBODIES
#455FRAGMENT SIZE CHARACTERIZATION OF CELL-FREE DNA MUTATIONS FROM CLONAL HEMATOPOIESIS
#456CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS
#457ANTI-CHEMOKIN LIKE RECEPTOR 1 ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
#458CD47/PD-L1-TARGETING PROTEIN COMPLEX AND METHODS OF USE THEREOF
#459ANTI-B7-H3 ANTIBODY AND APPLICATION THEREOF
#460NOVEL ANTI-CD276 ANTIBODIES AND THE USES THEREOF
#461MULTIFUNCTIONAL ANTIBODY-LIGAND TRAPS TO COUNTERACT IMMUNE TOLERANCE
#462Methods Of Using Alternating Electric Fields And Checkpoint Inhibitors
#463COMPOSITIONS AND METHODS OF TREATING MELANOMA
#464ANTIGEN-BINDING MOLECULE
#465HETERODIMERIC PROTEIN AND APPLICATION THEREOF
#466IMMUNOMODULATORY MOLECULES AND USES THEREOF
#467METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS
#468HUMANIZED AND AFFINITY MATURED ANTIBODIES TO FcRH5 AND METHODS OF USE
#469Anti-B7-H4/Anti-4-1BB Bispecific Antibodies And Use Thereof
#470PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES BINDING TO B7H4 AND CD3
#471BISPECIFIC ANTIBODY AND APPLICATION THEREOF
#472THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF ANTI-CANCER AGENT(S) AND IMMUNE CHECKPOINT INHIBITOR(S)
#473Composition Comprising HDAC Inhibitor and Immune Checkpoin Inhibitor and Methods For Using the Same
#474COMPOSITION COMPRISING PD-L1 ANTIGEN-BINDING FRAGMENT AND USE THEREOF
#475INTERFERON RECEPTOR ANTAGONISTS AND USES THEREOF
#476DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
#477CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS
#478PHARMACEUTICAL COMPOSITION COMPRISING ANTI-PVRIG/TIGIT BISPECIFIC ANTIBODY
#479COMPOSITIONS AND METHODS FOR TREATING LATE STAGE LUNG CANCER
#480TARGETED INTERFERON ALPHA FUSION PROTEINS AND METHODS OF USE
#481NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof
#482COMBINATION RADIOTHERAPY
#483BAG6 SPECIFIC CHIMERIC ANTIGEN RECEPTOR, NUCLEIC ACID, BAG6 SPECIFIC CHIMERIC ANTIGEN RECEPTOR EXPRESSION PLASMID, BAG6 SPECIFIC CHIMERIC ANTIGEN RECEPTOR EXPRESSING CELL, USE THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER
#484INTRACELLULAR DELIVERY OF BIOMOLECULES TO MODIFY IMMUNE RESPONSE
#485ANTI-ACVR2A ANTIBODIES AND USES THEREOF
#486ANTI-CECAM6 ANTIBODIES WITH REDUCED SIDE-EFFECTS
#487ANTI-NECTIN4 ANTIBODIES AND MULTI-SPECIFIC PROTEIN COMPLEXES COMPRISING SUCH
#488MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#489Chimeric Antigen Receptor-Modified NK-92 Cells
#490CANCER TREATMENT COMBINATIONS
#491CD47/PD-L1-TARGETING PROTEIN COMPLEX AND METHODS OF USE THEREOF
#492ANTI-PD-L1 AND IL-2 CYTOKINES
#493MULTIVALENT ANTIBODY
#494SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
#495COMBINATION CANCER THERAPY WITH MEMORY NK CELLS AND ANTI-CANCER BISPECIFIC MOLECULES
#496NANOPARTICLES FOR CANCER TREATMENT
#497FUSION PROTEIN TARGETING BOTH CD3 AND CD137, PREPARATION METHOD THEREFOR AND USE THEREOF
#498MULTIVALENT ANTIBODY
#499Immunomodulatory Il-2 Agents in Combination With Immune Checkpoint Inhibitors
#500COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET
#501ANTI-TIGIT ANTIBODY AND USE THEREOF
#502Antibody Masking Domains
#503IL-2/IL-15RBETAGAMMA AGONIST COMBINATION WITH ANTIBODY-DRUG CONJUGATES FOR TREATING CANCER
#504BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
#505IDENTIFICATION AND ELIMINATION OF DAMAGED AND/OR SENESCENT CELLS
#506MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY
#507B7-H3 ANTIBODY AND USE THEREOF
#508ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES
#509PHARMACEUTICAL COMPOSITION FOR TREATING SMALL CELL LUNG CANCER
#510Anti-Pvrig/Anti-Tigit Bispecific Antibodies And Applications Thereof
#511NOVEL BIFUNCTIONAL MULTISPECIFIC ANTAGONISTS CAPABLE OF INHIBITING MULTIPLE LIGANDS OF TGF-BETA FAMILY AND USES THEREOF
#512BISPECIFIC ANTIBODIES AND USES THEREOF
#513HOMOLOGOUS DIMERIZATION PEPTIDES AND ANTIBODIES COMPRISING THE SAME
#514DUAL-BLOCKADE OF IL-4 SIGNALING AND IMMUNE CHECKPOINT PROTEINS FOR TREATING CANCER
#515PHARMACEUTICAL COMPOSITIONS OF A B7-H3 ANTIBODY AND USE OF THE SAME
#516NOVEL MULTI-SPECIFIC MOLECULES
#517RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
#518NOVEL CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELLS EXPRESSING SAME
#519USE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA (PGC1ALPHA) AGONISTS TO IMPROVE EX VIVO EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS)
#520Use Of Methanol And Prodrugs Thereof In Therapy
#521DEPLETING MONOCLONAL ANTIBODIES AGAINST NATURAL KILLER CELLS
#522SYNTHETIC NUCLEIC ACID ELEMENTS FOR ENHANCING CAR T CELL EFFICACY
#523METHODS AND COMPOSITIONS FOR PKC-DELTA INHIBITION AND CANCER IMMUNOTHERAPY
#524METHODS AND COMPOSITION FOR THE SELECTIVE ENHANCEMENT OF ADOPTIVE CELL THERAPY
#525FUSION PROTEINS COMPRISING SUPPRESSION OF TUMORIGENICITY 2 OR INTERLEUKIN-33, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS
#526Chimeric Antigen Receptors with BCMA Specificity and Uses Thereof
#527MODIFIED IMMUNE CELL AND USE THEREOF
#528POLYPEPTIDE COMPLEXES WITH IMPROVED STABILITY AND EXPRESSION
#529B7-H4 ANTIBODY DOSING REGIMENS
#530ANTI-PD-L1 ANTIBODY AND USE THEREOF
#531ANTI-B7-H3 MONOCLONAL ANTIBODY AND USE THEREOF
#532ANTIBODIES AGAINST PD-L1
#533CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF
#534Scaffold proteins
#535NK CELL ENGAGER MOLECULES AND METHODS OF USE
#536Human Antibodies To PD-1
#537METHODS OF TREATING CANCER USING RECOMBINANT MICROORGANISMS EXPRESSING A STING AGONIST
#538IMMUNE CELLS ENGINEERED TO PROMOTE THANOTRANSMISSION AND USES THEREOF
#539METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#540ANTI-CD25 ANTIBODY AGENTS
#541ANTI-B7-H4 ANTIBODIES AND USES THEREOF
#542METHODS AND COMPOSITIONS FOR DECREASING SOLUBLE IMMUNE RECEPTOR CD28
#543IL-2 MUTEINS FOR TREATING CANCER OR INFECTION
#544ADIPONECTIN ALONE OR IN COMBINATION WITH EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR IMMUNE RELATED ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITORS
#545BCG and IL-15 based molecules
#546IL-15-based molecules with anti-CD20 antibody and methods of use
#547Anti-SIRPα antibodies and methods of use thereof
#548Anti-PD-L1 Antibody and Usethereof
#549ANTIBODY SPECIFICALLY BINDING WITH PD-L1 AND ANTIGEN-BINDING FRAGMENT OF ANTIBODY
#550ANTI-FOLR1 IMMUNOCONJUGATES AND ANTI-PD-1 ANTIBODY COMBINATIONS
#551CANCER THERAPIES COMPRISING PEPTIDE LOADED CXCR3- AND CCR5-INDUCING DENDRITIC CELLS AND CHEMOKINE MODULATORY AGENTS
#552ADAPTER POLYPEPTIDES AND METHODS OF USING THE SAME
#553METHOD FOR STIMULATING TUMOR-INFILTRATING LYMPHOCYTES WITH AN IL-15:IL-15R COMPLEX
#554IMMUNOMODULATOR COMPOSITION COMPRISING AZVUDINE
#555BISPECIFIC FUSION PROTEIN
#556ANTI-VTCN1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#557Immune checkpoint inhibitor combinations
#558THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
#559ANTI-MERTK ANTIBODIES AND METHODS OF USE THEREOF
#560BISPECIFIC MOLECULE SPECIFICALLY BINDING TO B7-H3 AND TGFB AND USES THEREOF
#561ANTI-PDL1 ANTIBODIES AND USES THEREOF
#562SEQUENTIAL INNATE AND ADAPTIVE IMMUNE MODULATION FOR CANCER TREATMENT
#563COMBINATION THERAPY FOR TREATING PIK3CA-MUTATED CANCER
#564COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR
#565MONOVALENT ANTI-MERTK ANTIBODIES AND METHODS OF USE THEREOF
#566METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER
#567BISPECIFIC ANTI-MERTK AND ANTI-PDL1 ANTIBODIES AND METHODS OF USE THEREOF
#568CELLS EXPRESSING VISTA ANTIGEN-BINDING MOLECULES
#569METHOD OF TREATING CANCER BY ADMINISTRATION OF AN ANTI-PD-1 OR ANTI-PD-L1 THERAPEUTIC AGENT VIA A LYMPHATIC MICRONEEDLE DELIVERY DEVICE
#570Combination Treatment of Cancer
#571ANTI-CD276 MAB TO TARGET BREAST CANCER
#572CHIMERIC PROTEINS AND METHODS OF IMMUNOTHERAPY
#573MULTI-SPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF
#574VEGFR-ANTIBODY LIGHT CHAIN FUSION PROTEIN
#575SIGLEC-9 ECD Fusion Molecules and Methods of Use Thereof
#576IMMUNO-ONCOLOGY THERAPEUTIC COMPOSITION USING ADJUVANT INCLUDING LIPOPEPTIDES AND POLY (I:C)
#577Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus
#578PHARMACEUTICAL KITS AND USES THEREOF FOR TREATING COLORECTAL CANCER
#579Vitro and Xenograft Anti-Tumor Activity of a Halogenated-Xanthene Against Refractory Pediatric Solid Tumors
#580BISPECIFIC CYTOTOXIC LYMPHOCYTE OR MACROPHAGE-REDIRECTING AUTOANTIBODIES, METHODS FOR PRODUCTION THEREOF AND METHODS OF TREATMENT
#581CROSS SPECIES SINGLE DOMAIN ANTIBODIES TARGETING PD-L1 FOR TREATING SOLID TUMORS
#582Antigen-binding polypeptide targeting B7H3 and application thereof
#583SPECIFIC BINDING PROTEIN TARGETING PD-L1 AND CD73
#584BIOMARKER FOR PREDICTING RESPONSE TO CANCER TREATMENT
#585COMBINATION DOSAGE REGIME OF CD137 AND PD-L1 BINDING AGENTS
#586ANTI-TIGIT ANTIBODY AND DOUBLE ANTIBODY AND THEIR APPLICATION
#587MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND USES THEREOF
#588ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOF
#589IL-15-BASED MOLECULES AND METHODS OF USE THEREOF
#590UNIQUE CANCER ASSOCIATED FIBROBLAST SUBSETS PREDICT RESPONSE TO IMMUNOTHERAPY
#591COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER
#592PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
#593BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO CD47 AND PD-L1
#594COMPOSITIONS AND METHODS FOR PRODUCING AND USING CELL-BASED IMMUNOTHERAPIES TO TARGET TUMORS
#595Compositions comprising IL-15N72D-based molecules and bacillus calmette-guerin (BCG)
#596Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
#597METHODS AND COMPOSITIONS FOR PANCREATIC CANCER EVALUATION AND TREATMENT
#598BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#599FULLY HUMAN ANTIBODY FOR HUMAN B7H3, CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF
#600PREDICTIVE PERIPHERAL BLOOD BIOMARKER FOR CHECKPOINT INHIBITORS